To ensure the safety and quality of medicinal products, Taiwan has fully implemented the international PIC/S GMP standards, and the pharmaceutical manufacturers could apply for GMP certificates from the Taiwan Food and Drug Administration (TFDA) after inspection and found in compliance with PIC/S GMP.

As technology advances and markets globalize, TFDA is committed to digital transformation, aligning with international digital trends. Starting from July 31, 2024 beside hard copy, the TFDA also began issuing digital GMP certificates, which include a digital signature. These digital certificates are encrypted using a digital signature that meets the global Adobe Approved Trust List and Taiwan’s Electronic Signatures Act,  can quickly verify via scanning  QR code or uploading  PDF file to a verification platform, and more than a thousand times verifications have been conducted since plateform launched, clearly demonstrating that the global competitiveness  of Taiwan’s pharmaceutical manufactures has been effectively boosted.

The TFDA emphasizes its commitment to ensuring that the public has access to pharmaceutical products of equivalent to those found in advanced contries, and enhancing the international competitiveness of Taiwan's pharmaceutical manufacturers. TFDA will continue to enhance the  management of pharmaceutical manufacturers, align with the policy of digital governance, and strive to achieve the goal of guaranteeing the safety and quality of pharmaceuticals for the World.